These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316 [TBL] [Abstract][Full Text] [Related]
9. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168 [TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis. Guo Q; Gao J; Guo H; Xie J; Cheng J Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923 [TBL] [Abstract][Full Text] [Related]
13. Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis". Noguchi Y; Yan M Int J Cancer; 2023 Jul; 153(1):238-239. PubMed ID: 36891933 [No Abstract] [Full Text] [Related]
14. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698 [TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review. Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661 [TBL] [Abstract][Full Text] [Related]
16. Reply to: Comments on "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis". Gu T; Lin A; Wang H; Zhang J; Luo P Int J Cancer; 2023 Jul; 153(1):240-242. PubMed ID: 36891965 [No Abstract] [Full Text] [Related]
18. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study. Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771 [TBL] [Abstract][Full Text] [Related]
19. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020. Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058 [TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. Wang H; Yang H; Zhou X; Zhang X Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]